Our partner is focused on developing precision medicines using their advanced computational platform to design small molecules that target specific disease-causing proteins. Their approach aims to address unmet medical needs, particularly in cancer, autoimmune diseases, and metabolic disorders, to improve patient outcomes.

This critical hire, reported to the Chief Medical Officer, and led the strategic direction and operational aspects for Regulatory Affairs, responsible for all regulatory aspects related to CMC, preclinical, and clinical development globally.